David Tulasne

Years Active: 2020-2024
Publications (10 Years): 7

UMR Canther, INSERM 1277, CNRS 9020, Univ Lille, Institut Pasteur de Lille, CHU Lille

Université de Lille (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

UMR Canther, INSERM 1277, CNRS 9020, Univ Lille, Institut Pasteur de Lille, CHU Lille Jan 01 2020

France

DR INSERM

Education History

Université de Lille Sep 01 1995 - Jul 01 1998

France

PHD

Publications

Célia Guérin, David Tulasne
Recording and classifying MET receptor mutations in cancers. eLife 13 (2024)
Célia Guérin, David Tulasne
Recording and classifying MET receptor mutations in cancers. eLife 13 (2024)
Célia Guérin, David Tulasne
Recording and classifying MET receptor mutations in cancers. eLife 13 (2024)
Célia Guérin, David Tulasne
Recording and classifying MET receptor mutations in cancers. eLife 13 (2024)
Marie Fernandes, Sonia Paget, Zoulika Kherrouche, Marie-José Truong, Audrey Vinchent, Jean-Pascal Meneboo, Shéhérazade Sebda, Elisabeth Werkmeister, Clotilde Descarpentries, Martin Figeac, Alexis B Cortot, David Tulasne
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site. FEBS letters (2023)
Marie Fernandes, Philippe Jamme, Alexis B Cortot, Zoulika Kherrouche, David Tulasne
When the MET receptor kicks in to resist targeted therapies. Oncogene 40 (24) (2021)
Leslie Duplaquet, Catherine Leroy, Audrey Vinchent, Sonia Paget, Jonathan Lefebvre, Fabien Vanden Abeele, Steve Lancel, Florence Giffard, Réjane Paumelle, Gabriel Bidaux, Laurent Heliot, Laurent Poulain, Alessandro Furlan, David Tulasne
Control of cell death/survival balance by the MET dependence receptor. eLife 9 (2020)

David Tulasne.css-eqlu8i{font-size:small;padding-left:4px;}